Rankings and Reviews Methodology

Updated September 21, 2026, 6:36 AM

GenoMethods publishes rankings, comparisons and reviews when structured evaluation helps readers understand biotechnology companies, platforms, research tools, technologies or development landscapes.

A ranking is not used simply to create an ordered list. The comparison should have a meaningful subject, reasonably comparable entities and enough supporting information to explain the differences that matter to readers.

What We Evaluate

biotechnology companies;
research and biotechnology platforms;
sequencing and genomics technologies;
bioinformatics tools;
AI-in-biology and AI-assisted drug-discovery platforms;
diagnostic technologies;
genome-editing technologies;
gene and cell therapy platforms;
therapeutic modalities;
clinical-development landscapes;
data-driven biotechnology lists.

Sources

Depending on the ranking or review, GenoMethods may use:

official company information;
peer-reviewed scientific literature;
regulatory databases and documents;
clinical trial registries;
company filings;
public scientific datasets;
technical documentation;
public pricing information where reliable;
patent and licensing information;
original editorial research;
qualified expert input where useful;
reputable secondary reporting for context.

Source availability can differ substantially between public companies, private companies, experimental technologies and commercially available tools. Those differences may limit how directly entities can be compared.

Evaluation Criteria

Scientific and technical relevance: Whether the technology addresses a meaningful biotechnology problem and is appropriately comparable with other entities in the category. A technically interesting product is not automatically comparable with a platform designed for a different stage or use case.
Evidence and validation: Scientific validation, benchmarking, replication, clinical evidence or regulatory documentation where relevant. The weight of evidence depends on the maturity and purpose of the technology being assessed.
Capabilities and features: Specifications, workflow compatibility, performance, scalability, use cases and limitations. Feature counts alone do not necessarily establish practical or scientific value.
Data quality and transparency: Availability and clarity of methodology, performance data and technical information. Missing or incomparable information may limit the confidence of an assessment.
Safety and regulatory status: Safety evidence, regulatory status or compliance requirements where relevant to the technology or intended use.
Availability: Whether a product or platform is commercially available, experimental, research-use only or geographically limited.
Pricing and value: Pricing may be considered where reliable and comparable public information exists. GenoMethods does not invent pricing solely to create a comparison.
User and workflow considerations: Integration, usability, technical requirements and practical workflow demands when those factors are relevant to the type of product or platform.
Track record: Documented development history, publication record, partnerships, regulatory history or other relevant evidence that helps place the current product or company in context.
Update frequency: Continued development and update frequency may matter for software, databases and rapidly changing platforms.

How Scientific Evidence Is Compared

Computational prediction vs experimental validation Predicted performance may not reproduce experimentally, so evidence from these stages should not be treated as interchangeable.

Preclinical vs human clinical evidence Animal or laboratory findings can support development but do not establish patient benefit.

Early activity vs established clinical benefit Durability, safety, follow-up and comparative outcomes may remain uncertain.

Regulatory designation vs approval Designations can support or accelerate development without establishing marketing approval.

Scientific feasibility vs commercial readiness A functioning scientific method may still face manufacturing, regulatory, operational or market constraints.

Scoring and Weighting

Not all GenoMethods rankings use numerical scores. A numerical score should not be introduced where the available evidence does not support meaningful numerical precision.

Some comparisons may use editorial ordering based on disclosed criteria, while others may group entities by category, development stage or technology type.

If numerical scoring is used, the relevant ranking should explain the principal factors affecting the score.

Numerical precision should not imply certainty beyond the underlying evidence.

Commercial Separation

GenoMethods does not currently sell paid ranking positions, paid editorial scores or guaranteed favorable reviews.

Google AdSense advertising is separate from ranking methodology. Affiliate links are not currently used as part of the standard publishing model.

Updates and Corrections

Rankings may change when new scientific evidence, regulatory decisions, product changes, company developments, pricing or availability materially affects the assessment. An update should reflect a genuine change in the information relevant to the methodology.

If a factual error affects a ranking, GenoMethods may correct the underlying information and reconsider the ordering.

Limitations

public information may be incomplete;
private companies may disclose less information;
scientific evidence changes;
pricing and specifications may change;
availability may vary by geography;
different readers may value different criteria.

Rankings are informational editorial resources and do not guarantee scientific, clinical, financial or commercial outcomes. A ranking should be understood in the context of the methodology and evidence available at the time of the evaluation.

Feedback

General: livelong@genomethods.org

Corrections: corrections@genomethods.org

GenoMethods
1 Broadway
Cambridge, MA 02142
United States